NEPA@ was significantly more effective than PALO and numerically better than APR + OND for all secondary efficacy endpoints of no emesis , no significant nausea , and complete protection ( CR plus no significant nausea ) rates during the acute ( @-@ h ) , delayed ( @-@ h ) , and overall phases .